Bank of America Securities analyst Kevin Fischbeck reiterated a Sell rating on Centene yesterday and set a price target of $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kevin Fischbeck has given his Sell rating due to a combination of factors impacting Centene’s future performance. Despite the company’s expectations for EPS growth in 2026, there is low visibility into the performance of its Medicaid and Exchange segments, which poses significant uncertainty. The company’s Medicaid segment is expected to see slight attrition in enrollment due to redeterminations, and while work requirements are not seen as a major headwind in 2026, they could impact performance in subsequent years.
Additionally, the Exchange market faces challenges with higher-than-expected costs and a projected contraction in enrollment by 2026. Although there is potential for margin improvement in the Marketplace and Medicare Advantage segments, the overall outlook remains cautious. The analyst has raised the price objective to $32, reflecting these uncertainties and maintaining an Underperform rating due to the limited clarity on future performance in key areas.
In another report released on October 14, Goldman Sachs also initiated coverage with a Sell rating on the stock with a $34.07 price target.
CNC’s price has also changed moderately for the past six months – from $59.260 to $37.340, which is a -36.99% drop .